Trial Profile
Phase II Study of Axitinib in Patients With Neurofibromatosis Type 2 and Progressive Vestibular Schwannomas
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 03 Dec 2021
Price :
$35
*
At a glance
- Drugs Axitinib (Primary)
- Indications Acoustic neuroma; Neurofibromatosis 2
- Focus Pharmacodynamics; Pharmacokinetics
- 23 Feb 2021 Status changed from active, no longer recruiting to completed.
- 13 May 2019 Planned End Date changed from 5 Apr 2020 to 5 Feb 2020.
- 06 May 2019 Planned End Date changed from 24 Jan 2020 to 5 Apr 2020.